Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

IMPORTANCE: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering improved survival outcomes are therefore needed. OBJECT...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Oncol
Hauptverfasser: Shroff, Rachna T., Javle, Milind M., Xiao, Lianchun, Kaseb, Ahmed O., Varadhachary, Gauri R., Wolff, Robert A., Raghav, Kanwal P. S., Iwasaki, Michiko, Masci, Peter, Ramanathan, Ramesh K., Ahn, Daniel H., Bekaii-Saab, Tanios S., Borad, Mitesh J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2019
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567834/
https://ncbi.nlm.nih.gov/pubmed/30998813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0270
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge